Evidence-Based Complementary and Alternative Medicine / 2013 / Article / Tab 1 / Research Article
Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series Table 1 Demographic and clinical characteristics of all patients (
).
Patient number Gender Age BMI Diagnosis day Initial stage* Prior surgery Differentiation Prior adjuvant treatment Day of advanced stage diagnosis Metastasis region Chemotherapy regimen Response 1 Female 65 23.4 2005-07-15 I PPPD NA 2006-07-15 Liver (1) Clinical trial 4 cycles PD 2 Female 61 20.6 2005-04-25 IIB PPPD Well 2005-12-30 Metastatic LN (1) Oral FU/CDDP 15 cycles PD 3 Female 58 25.2 2006-08-07 IV PPPD (R2) Moderate Lung, LN (1) Oral FU with concurrent RT 1 cycles PD 4 Female 36 18.5 2008-05-20 IIB PPPD Moderate 2008-12-15 Lung, bone, LN (1) Gemcitabine/CDDP 8 cycles PD 5 Male 66 24.7 2006-12-18 IB PPPD NA IV FU with concurrent RT 2007-08-21 Liver (1) Oral FU/CDDP 21 cycles PD 6 Female 45 20.1 2010-03-31 IV Poor Liver (1) IV FU/CDDP/EPS 3 cycles PD 7 Male 68 17.9 2009-08-04 IIB PPPD Moderate 2009-12-02 Lung, LN (1) Oral FU/CDDP 8 cycles PD 8 Male 41 20.8 2010-03-17 IV Well Liver (1) Oral FU/Oxaliplatin 6 cycles SD 9 Male 46 19.7 2009-08-05 IIB PPPD NA 2010-12-01 Peritoneal seeding Chemotherapy refused because of adverse effects 10 Female 41 14.6 2009-09-22 IIB PPPD Moderate Oral FU 2 cycles 2010-02-06 Lung, liver Chemotherapy refused because of adverse effects 11 Female 73 22.6 2010-06-14 IIA PPPD Well 2011-02-09 Peritoneal seeding Chemotherapy refused because of old age 12 Male 37 19.3 2008-11-15 IIB PPPD Moderate 2009-10-15 Mesenteric LN (1) Oral FU with concurrent RT 1 cycles PD
Staging is based on the seventh edition of the TNM Classification of Malignant Tumors .
